XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Beginning balance (in shares) at Dec. 31, 2023   73,366,766        
Beginning balance at Dec. 31, 2023 $ 52,341 $ 7 $ 595,781 $ (23,555) $ (519,892) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (32,923)       (32,923)  
Issuance of common stock to directors (in shares)   4,974        
Vesting of restricted stock units (in shares)   141,563        
Vesting of restricted stock units (2,862)   (2,862)      
Exercise of stock options (in shares)   43,460        
Exercise of stock options 345   345      
Repurchase of common stock (in shares)   (1,320,531)        
Repurchase of common stock (50,019)         (50,019)
Stock-based compensation expense 10,606   10,606      
Other comprehensive (loss) income 12,847     12,847    
Ending balance (in shares) at Mar. 31, 2024   72,236,232        
Ending balance at Mar. 31, 2024 (9,665) $ 7 603,870 (10,708) (552,815) (50,019)
Beginning balance (in shares) at Dec. 31, 2023   73,366,766        
Beginning balance at Dec. 31, 2023 52,341 $ 7 595,781 (23,555) (519,892) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (78,615)          
Ending balance (in shares) at Sep. 30, 2024   72,429,625        
Ending balance at Sep. 30, 2024 (49,801) $ 7 614,204 (22,809) (598,507) (42,696)
Beginning balance (in shares) at Mar. 31, 2024   72,236,232        
Beginning balance at Mar. 31, 2024 (9,665) $ 7 603,870 (10,708) (552,815) (50,019)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (43,592)       (43,592)  
Issuance of common stock to directors (in shares)   4,692        
Issuance of common stock to directors 0   (178)     178
Vesting of restricted stock units (in shares)   77,116        
Vesting of restricted stock units (1,360)   (4,279)     2,919
Exercise of stock options (in shares)   25,037        
Exercise of stock options 163   (785)     948
Stock-based compensation expense 9,900   9,900      
Other comprehensive (loss) income (1,104)     (1,104)    
Ending balance (in shares) at Jun. 30, 2024   72,343,077        
Ending balance at Jun. 30, 2024 (45,658) $ 7 608,528 (11,812) (596,407) (45,974)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (2,100)       (2,100)  
Issuance of common stock to directors (in shares)   5,060        
Issuance of common stock to directors 0   (192)     192
Vesting of restricted stock units (in shares)   69,362        
Vesting of restricted stock units (662)   (3,289)     2,627
Exercise of stock options (in shares)   12,126        
Exercise of stock options 111   (348)     459
Stock-based compensation expense 9,505   9,505      
Other comprehensive (loss) income (10,997)     (10,997)    
Ending balance (in shares) at Sep. 30, 2024   72,429,625        
Ending balance at Sep. 30, 2024 (49,801) $ 7 614,204 (22,809) (598,507) (42,696)
Beginning balance (in shares) at Dec. 31, 2024   74,028,786        
Beginning balance at Dec. 31, 2024 (32,640) $ 7 591,281 (11,774) (612,154) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (1,177)       (1,177)  
Issuance of common stock to directors (in shares)   4,735        
Vesting of restricted stock units (in shares)   167,726        
Vesting of restricted stock units (3,199)   (3,199)      
Exercise of stock options (in shares)   18,953        
Exercise of stock options 190   190      
Stock-based compensation expense 8,814   8,814      
Other comprehensive (loss) income (3,733)     (3,733)    
Ending balance (in shares) at Mar. 31, 2025   74,220,200        
Ending balance at Mar. 31, 2025 (31,745) $ 7 597,086 (15,507) (613,331) 0
Beginning balance (in shares) at Dec. 31, 2024   74,028,786        
Beginning balance at Dec. 31, 2024 (32,640) $ 7 591,281 (11,774) (612,154) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) $ 6,336          
Ending balance (in shares) at Sep. 30, 2025 73,800,000 73,817,660        
Ending balance at Sep. 30, 2025 $ (48,544) $ 7 612,488 (35,221) (605,818) (20,000)
Beginning balance (in shares) at Mar. 31, 2025   74,220,200        
Beginning balance at Mar. 31, 2025 (31,745) $ 7 597,086 (15,507) (613,331) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (312)       (312)  
Issuance of common stock to directors (in shares)   5,686        
Vesting of restricted stock units (in shares)   77,082        
Vesting of restricted stock units (1,269)   (1,269)      
Exercise of stock options (in shares)   30,880        
Exercise of stock options 314   314      
Repurchase of common stock (in shares)   (313,160)        
Repurchase of common stock (10,000)         (10,000)
Stock-based compensation expense 8,953   8,953      
Other comprehensive (loss) income (19,682)     (19,682)    
Ending balance (in shares) at Jun. 30, 2025   74,020,688        
Ending balance at Jun. 30, 2025 (53,741) $ 7 605,084 (35,189) (613,643) (10,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) 7,825       7,825  
Issuance of common stock to directors (in shares)   6,276        
Vesting of restricted stock units (in shares)   92,669        
Vesting of restricted stock units (1,422)   (1,422)      
Exercise of stock options (in shares)   24,618        
Exercise of stock options 248   248      
Repurchase of common stock (in shares)   (326,591)        
Repurchase of common stock (10,000)         (10,000)
Stock-based compensation expense 8,578   8,578      
Other comprehensive (loss) income $ (32)     (32)    
Ending balance (in shares) at Sep. 30, 2025 73,800,000 73,817,660        
Ending balance at Sep. 30, 2025 $ (48,544) $ 7 $ 612,488 $ (35,221) $ (605,818) $ (20,000)